Voyager’s tau-reducing therapies show promise in preclinical studies
VY-TAU01, Voyager Therapeutics’s investigational therapy designed to prevent the formation of harmful tau tangles in the brains of people with Alzheimer’s disease, was well tolerated and showed promising pharmacological properties in preclinical studies. Based on these findings, the company expects to submit an application to the U.S. Food…